Citations (25)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Shashi N. Kapadia, Judith L. Griffin, Justine Waldman, Nicolas R. Ziebarth, Bruce R. Schackman & Czarina N. Behrends. (2022) The Experience of Implementing a Low-Threshold Buprenorphine Treatment Program in a Non-Urban Medical Practice. Substance Use & Misuse 57:2, pages 308-315.
Read now
Read now
Taeko Frost, Sarah Deutsch, Shoshana Brown, Ellen Lemien, Chinazo O. Cunningham & Aaron D. Fox. (2021) “We’ll be able to take care of ourselves” – A qualitative study of client attitudes toward implementing buprenorphine treatment at syringe services programs. Substance Abuse 42:4, pages 983-989.
Read now
Read now
Benjamin T. Hayes, Andrea Jakubowski, Christine Fitzsimmons, Billy Garcia, Franklin Ramirez & Aaron D. Fox. (2021) “The Doctor Says You Cannot Have [Buprenorphine]” Autonomy and Use of Prescribed or Non-Prescribed Buprenorphine. Substance Use & Misuse 56:8, pages 1137-1143.
Read now
Read now
Marcus A. Bachhuber$suffix/text()$suffix/text(), Cole Thompson$suffix/text()$suffix/text(), Ann Prybylowski$suffix/text()$suffix/text(), José Benitez$suffix/text()$suffix/text(), Silvana Mazzella$suffix/text()$suffix/text() & David Barclay$suffix/text()$suffix/text(). (2018) Description and outcomes of a buprenorphine maintenance treatment program integrated within Prevention Point Philadelphia, an urban syringe exchange program. Substance Abuse 39:2, pages 167-172.
Read now
Read now
Anthony Estreet, Paul Archibald, M. Taqi Tirmazi, Sapphire Goodman & Tracy Cudjoe. (2017) Exploring social work student education: The effect of a harm reduction curriculum on student knowledge and attitudes regarding opioid use disorders. Substance Abuse 38:4, pages 369-375.
Read now
Read now
Adam J. Gordon & Jennifer A. Jenkins. (2015) The Time Is Now: The Role of Pharmacotherapies in Expanding Treatment for Opioid Use Disorder. Substance Abuse 36:2, pages 127-128.
Read now
Read now
Articles from other publishers (19)
Joëlla W. Adams, Michael Duprey, Sazid Khan, Jessica Cance, Donald P. Rice & Georgiy Bobashev. (2023) Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study. Harm Reduction Journal 20:1.
Crossref
Crossref
Yangxi An, Christopher J. Hoffmann, Urvisha Bhoora, Pretty Ndini, Derrick Moyo, Laura Steiner, Sukholuhle Tshuma, Tonderai Mabuto, Jannie Hugo, Jill Owczarzak & Tessa S. Marcus. (2023) Opioid use and HIV treatment services experiences among male criminal justice-involved persons in South Africa: a qualitative study. Harm Reduction Journal 20:1.
Crossref
Crossref
Andrea Jakubowski, Sabrina Fowler & Aaron D. Fox. (2023) Three decades of research in substance use disorder treatment for syringe services program participants: a scoping review of the literature. Addiction Science & Clinical Practice 18:1.
Crossref
Crossref
Shashi N Kapadia, Benjamin J Eckhardt, Jared A Leff, Chunki Fong, Pedro Mateu-Gelabert, Kristen M Marks, Yesenia Aponte-Melendez & Bruce R Schackman. (2022) Cost of providing co-located hepatitis C treatment at a syringe service program exceeds potential reimbursement: Results from a clinical trial. Drug and Alcohol Dependence Reports 5, pages 100109.
Crossref
Crossref
Joëlla W. Adams, Alexandra Savinkina, Aaron Fox, Czarina N. Behrends, Rajapaksha W. M. A. Madushani, Jianing Wang, Avik Chatterjee, Alexander Y. Walley, Joshua A. Barocas & Benjamin P. Linas. (2022) Modeling the cost‐effectiveness and impact on fatal overdose and initiation of buprenorphine–naloxone treatment at syringe service programs. Addiction 117:10, pages 2635-2648.
Crossref
Crossref
Andrea Jakubowski, Brianna L. Norton, Benjamin T. Hayes, Brent E. Gibson, Christine Fitzsimmons, L. Synn Stern, Franklin Ramirez, Mercedes Guzman, Susan Spratt, Pia Marcus & Aaron D. Fox. (2022) Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes. Journal of Addiction Medicine 16:4, pages 447-453.
Crossref
Crossref
Andrea M. LopezMatthew ThomannZena DhattJulieta FerreraMarwa Al-NassirMaggie AmbroseShane Sullivan. (2022) Understanding Racial Inequities in the Implementation of Harm Reduction Initiatives. American Journal of Public Health 112:S2, pages S173-S181.
Crossref
Crossref
Ian David Aronson, Alex S Bennett, Mary-Andrée Ardouin-Guerrier, German Rivera-Castellar, Brent Gibson, Samantha Santoscoy & Brittney Vargas-Estrella. (2022) How Vaccine Ambivalence Can Lead People Who Inject Drugs to Decline COVID-19 Vaccination and Ways This Can Be Addressed: Qualitative Study. JMIR Formative Research 6:3, pages e35066.
Crossref
Crossref
Brandon del Pozo. (2021) CommunityStat: A Public Health Intervention to Reduce Opioid Overdose Deaths in Burlington, Vermont, 2017–2020. Contemporary Drug Problems 49:1, pages 3-19.
Crossref
Crossref
Andres Perez-Correa, Bilal Abbas, Lindsey Riback, Megan Ghiroli, Brianna Norton, Sean Murphy, Andrea Jakubowski, Benjamin T. Hayes, Chinazo O. Cunningham & Aaron D. Fox. (2022) Onsite buprenorphine inductions at harm reduction agencies to increase treatment engagement and reduce HIV risk: Design and rationale. Contemporary Clinical Trials 114, pages 106674.
Crossref
Crossref
Kristi Hill, Laura Nussdorf, Julia D. Mount, Rachel Silk, Chloe Gross, David Sternberg, Phyllis Bijole, Miriam Jones, Randy Kier, Dana Mccullough, Poonam Mathur, Shyam Kottilil, Henry Masur, Sarah Kattakuzhy & Elana S. Rosenthal. (2022) Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment. Journal of Addiction Medicine 16:1, pages 10-17.
Crossref
Crossref
Lynn D. Wenger, Alex H. Kral, Ricky N. Bluthenthal, Terry Morris, Lee Ongais & Barrot H. Lambdin. (2021) Ingenuity and resiliency of syringe service programs on the front lines of the opioid overdose and COVID-19 crises. Translational Research 234, pages 159-173.
Crossref
Crossref
Theresa Winhusen, Alexander Walley, Laura C. Fanucchi, Tim Hunt, Mike Lyons, Michelle Lofwall, Jennifer L. Brown, Patricia R. Freeman, Edward Nunes, Donna Beers, Richard Saitz, Leyla Stambaugh, Emmanuel A. Oga, Nicole Herron, Trevor Baker, Christopher D. Cook, Monica F. Roberts, Daniel P. Alford, Joanna L. Starrels & Redonna K. Chandler. (2020) The Opioid-overdose Reduction Continuum of Care Approach (ORCCA): Evidence-based practices in the HEALing Communities Study. Drug and Alcohol Dependence 217, pages 108325.
Crossref
Crossref
Robert G. Carlson, Raminta Daniulaityte, Sydney M. Silverstein, Ramzi W. Nahhas & Silvia S. Martins. (2020) Unintentional drug overdose: Is more frequent use of non-prescribed buprenorphine associated with lower risk of overdose?. International Journal of Drug Policy 79, pages 102722.
Crossref
Crossref
Julia Dickson-Gomez, Wamala Twaibu, Erica Christenson, Katende Dan, Ronald Anguzu, Ethan Homedi & Nazarius Mbona Tumwesigye. (2020) Injection and sexual risk among people who use or inject drugs in Kampala, Uganda: An exploratory qualitative study. PLOS ONE 15:4, pages e0231969.
Crossref
Crossref
Jamie Carter, Barry Zevin & Paula J. Lum. (2019) Low barrier buprenorphine treatment for persons experiencing homelessness and injecting heroin in San Francisco. Addiction Science & Clinical Practice 14:1.
Crossref
Crossref
Rachel L. Snow, Rachel E. Simon, Helen E. Jack, Devin Oller, Laura Kehoe & Sarah E. Wakeman. (2019) Patient experiences with a transitional, low-threshold clinic for the treatment of substance use disorder: A qualitative study of a bridge clinic. Journal of Substance Abuse Treatment 107, pages 1-7.
Crossref
Crossref
Aaron D. Fox, Andrea U. Jakubowski & Jonathan Giftos. 2019. Treating Opioid Addiction. Treating Opioid Addiction
197
222
.
Aaron D. Fox, Nancy L. Sohler, Taeko Frost, Carolina Lopez & Chinazo O. Cunningham. (2017) Development and evaluation of a community-based buprenorphine treatment intervention. Harm Reduction Journal 14:1.
Crossref
Crossref